Cargando…

Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF‐PU.1‐DPP4 Axis

Colorectal cancer (CRC) metastasizes mainly to the liver, which accounts for the majority of CRC‐related deaths. Here it is shown that metastatic cells undergo specific chromatin remodeling in the liver. Hepatic growth factor (HGF) induces phosphorylation of PU.1, a pioneer factor, which in turn bin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lihua, Wang, Ergang, Prado Balcazar, Jorge, Wu, Zhenzhen, Xiang, Kun, Wang, Yi, Huang, Qiang, Negrete, Marcos, Chen, Kai‐Yuan, Li, Wei, Fu, Yujie, Dohlman, Anders, Mines, Robert, Zhang, Liwen, Kobayashi, Yoshihiko, Chen, Tianyi, Shi, Guizhi, Shen, John Paul, Kopetz, Scott, Tata, Purushothama Rao, Moreno, Victor, Gersbach, Charles, Crawford, Gregory, Hsu, David, Huang, Emina, Bu, Pengcheng, Shen, Xiling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498885/
https://www.ncbi.nlm.nih.gov/pubmed/34378358
http://dx.doi.org/10.1002/advs.202004673
Descripción
Sumario:Colorectal cancer (CRC) metastasizes mainly to the liver, which accounts for the majority of CRC‐related deaths. Here it is shown that metastatic cells undergo specific chromatin remodeling in the liver. Hepatic growth factor (HGF) induces phosphorylation of PU.1, a pioneer factor, which in turn binds and opens chromatin regions of downstream effector genes. PU.1 increases histone acetylation at the DPP4 locus. Precise epigenetic silencing by CRISPR/dCas9(KRAB) or CRISPR/dCas9(HDAC) revealed that individual PU.1‐remodeled regulatory elements collectively modulate DPP4 expression and liver metastasis growth. Genetic silencing or pharmacological inhibition of each factor along this chromatin remodeling axis strongly suppressed liver metastasis. Therefore, microenvironment‐induced epimutation is an important mechanism for metastatic tumor cells to grow in their new niche. This study presents a potential strategy to target chromatin remodeling in metastatic cancer and the promise of repurposing drugs to treat metastasis.